DSIP after PCAC: the sleep peptide that did not get a yes
When PCAC voted in July 2026, six peptides received recommendations toward 503A bulks-list consideration. Emideltide—better known in research circles as DSIP, delta sleep-inducing peptide—did not. That single “no” is now a permanent part of the 2026 compounding story. This article explains what DSIP is, why sleep marketing attached to it, and how to read the evidence without turning a committee vote into either a ban myth or a vindication narrative.
What DSIP is
DSIP is a nonapeptide historically investigated for sleep regulation and stress-related endpoints. The research lineage is decades old, with mixed and often methodologically limited human work by modern trial standards. It is not an FDA-approved insomnia drug.
Why it was on the PCAC table
Nominations to the 503A bulks process can place substances before FDA staff and the advisory committee even when commercial hype exceeds evidence. Staff briefing packages for the July slate repeatedly stressed thin human data across several nominees; DSIP’s sleep claims did not clear the committee’s recommendation threshold.
What a “no” vote means—and does not
A PCAC recommendation against listing is advisory input to FDA’s bulks rulemaking. It is not a criminal prohibition by itself, and it is not a scientific declaration that every paper on DSIP is false. It is a compounding-policy signal: the committee did not endorse DSIP for the 503A bulk pathway alongside the six “yes” peptides later named in HHS interim discretion materials.
Sleep evidence in plain language
Modern insomnia care guidelines prioritize CBT-I and approved pharmacologic options with characterized risk/benefit. DSIP does not sit in that guideline core. Older DSIP sleep studies are often small, heterogeneous, or lacking the replication expected for standard therapy. Educational interest is legitimate; substitution for evidence-based sleep medicine is not.
How DSIP relates to the HHS six
HHS’s October 2026 enforcement-discretion Appendix A tracks the PCAC yes set. DSIP is absent. That alignment is one of the cleanest “read the footnotes” lessons of the season: interim discretion is not a general peptide amnesty.
Research takeaway
Keep DSIP in the catalog as a historical and mechanistic curiosity with a clear regulatory footnote. For sleep health content, point readers to proven frameworks first and peptide hypotheses second.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.
Sources
- PCAC July 2026 outcomes
- HHS six-peptide guide
- FDA PCAC staff briefing materials (July 2026 docket)